– USA, NY – Curemark, LLC today announced the appointment of Chris Varelas to its Board of Directors.
“We are extremely excited to welcome Chris to our board. As Curemark’s growth continues to accelerate, his decades of experience in banking, finance and M&A will be invaluable as we navigate the path to commercialization,” said CEO and Founder, Dr. Joan Fallon.
About Christopher Varelas
Chris Varelas is a Co-founding Partner of Riverwood Capital, an investment firm focused on high-growth technology and technology-related companies. Before establishing Riverwood, he worked at Salomon Brothers/Citi as Global Head of Technology, Media, and Telecom Investment banking, served as Head of Citi’s National Investment Bank, and was a member of Citi’s Global Operating Committee. Chris Varelas was selected as one of the 100 most important deal-makers by the New York Times and was named the top “rainmaker” in the technology sector by Dealmaker Magazine. He is a trustee of the Aspen Institute, for which he recently founded the Aspen Finance Fellows program, dedicated to producing the next generation of leaders in financial services.
Chris Varelas said, “I am honored to be on this journey with such an amazing founder and team in pursuit of a noble and much-needed endeavor.”
About Curemark
Founded in 2007, Curemark is a private, clinical-stage biopharmaceutical company developing novel therapies for the treatment of serious unmet needs in neuro-developmental and neurodegenerative disorders. Curemark’s pipeline includes preclinical and clinical-stage programs for the treatment of autism, schizophrenia, Parkinson’s disease, ADHD, and addiction.
SOURCE: https://curemark.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.